GlassScriptPhysician profile
Sean Patrick Callahan
NPI 1043505670
$321,002.89
in general payments reported to CMS, 2019-2025
39 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,742 · 2020: $921 · 2021: $899 · 2022: $16K · 2023: $51K · 2024: $156K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $236K · Travel and Lodging: $30K · Food and Beverage: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $236,004.62 |
| Travel and Lodging | $29,677.64 |
| Food and Beverage | $15,017.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $261,392.20 | 2023-2025 | Galaxy |
| Ethicon INC. | $32,956.30 | 2019-2024 | Monarch Platform |
| Ethicon Endo-Surgery INC. | $7,237.61 | 2023 | |
| Pinnacle Biologics, INC | $3,935.11 | 2023 | Photofrin |
| Intuitive Surgical, INC. | $2,635.86 | 2019-2023 | Da Vinci Surgical System |
| Pulmonx Corporation | $2,581.40 | 2019-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Biomerieux INC | $2,111.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,248.34 | 2019-2025 | Ofev |
| Medical Device Business Services, INC. | $1,169.63 | 2023 | Monarch |
| Boston Scientific Corporation | $959.03 | 2022-2023 | |
| Galvanize Therapeutics, INC | $893.24 | 2023-2025 | Aliya System |
| Medtronic, INC. | $622.25 | 2021-2023 | Illumisite, Gencut |
| Glaxosmithkline, LLC. | $552.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inari Medical, INC. | $377.45 | 2021-2022 | |
| Insmed, INC. | $294.21 | 2019-2024 | Arikayce |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.